Table 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors | Synapse
October 8, 2025Open Access
Table 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
Puntos clave
Adverse events related to basroparib were summarized, indicating outcomes of treatment.
Patients with advanced-stage solid tumors showed varying responses during dose-escalation.
The phase I study evaluated the safety and tolerability of basroparib.
Considering the advanced-stage tumors, findings support ongoing research into tankyrase inhibitors.